Previous 10 | Next 10 |
- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed ...
SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin ...
89bio (NASDAQ:ETNB), a biotech known for its liver disease studies, is trading higher in the pre-market Thursday after Raymond James upgraded the stock to Strong Buy from Outperform, citing its potential in a lipid disorder called severe hypertriglyceridemia (SHTG). The company is advancing m...
89bio press release (NASDAQ:ETNB): Q1 GAAP EPS of -$1.26 beats by $0.03. As of March 31, 2022, 89bio had cash, cash equivalents, and short-term investments of $126.1 million. Based upon current projections, 89bio believes it has sufficient cash to fund operations into the second half of 2023....
- ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia (SHTG) patients remains on track with topline data expected in the second quarter of 2022 - - ENLIVEN Phase 2b NASH trial enrollment completion expected in the third quarter of 2022 followed by topline dat...
SAN FRANCISCO, April 26, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it will host a key...
89bio press release (NASDAQ:ETNB): Q4 GAAP EPS of -$1.30 misses by $0.03. As of December 31, 2021, 89bio had cash, cash equivalents, and short-term investments totaling $150.7 million compared to $204.7 million as of December 31, 2020. For further details see: 89bio GAAP EPS of -$1.30 m...
– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH – – ENLIVEN Phase 2b NASH trial on track for ...
- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of R...
The following slide deck was published by 89bio, Inc. in conjunction with this event. For further details see: 89bio (ETNB) Presents At Global Healthcare Virtual Conference - Slideshow
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...